Related Experiment Video
Updated: Apr 17, 2026
14:34
A Bilingual Computational Workflow for Identifying Potential PLK1 Inhibitors in American Sign Language and English
Published on: April 3, 2026
215
Catalyzing the Critical Path Initiative: FDA's progress in drug development activities
A Parekh1, S Buckman-Garner, S McCune
1Office of Translational Sciences, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA.
Clinical Pharmacology and Therapeutics
|February 12, 2015
Summary
The US Food and Drug Administration (FDA) modernized regulatory processes through stakeholder partnerships, yielding tangible results and ongoing initiatives. Continued collaboration is vital for advancing drug development and public health.
Area of Science:
- Regulatory Science
- Drug Development
- Public Health
Background:
- The drug development sector faces significant challenges.
- The US Food and Drug Administration (FDA) has focused on modernizing regulatory processes over the last decade.
- Stakeholder engagement is crucial for regulatory reform.
Purpose of the Study:
- To outline the FDA's modernization efforts in drug development.
- To highlight the importance of collaborative initiatives.
- To underscore the need for continued progress in regulatory science.
Main Methods:
- Review of FDA initiatives and partnerships.
- Analysis of stakeholder input and collaborative efforts.
- Assessment of progress and ongoing discussions in regulatory science.
Main Results:
- Multiple modernization initiatives have been launched, with several achieving tangible results.
- Collaborative efforts enhance knowledge sharing and overcome data/intellectual property challenges.
- Significant interest exists in partnering on public health regulatory science issues.
Conclusions:
- FDA's modernization efforts, driven by collaboration, are yielding positive outcomes.
- Overcoming data sharing and intellectual property hurdles is feasible through partnerships.
- Sustained collaborative efforts are essential to facilitate drug development and address public health needs.
Related Concept Videos
01:11Clinical Trials: Overview
5.5K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
5.5K
01:28Preclinical Development: Overview
6.6K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
6.6K
01:26FDA Approved Drugs: Changes to Approved Drugs
336
Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
336
01:25Drug Regulation
3.4K
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
3.4K
01:26Drug Administration and Therapy Phases: Overview
2.1K
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
2.1K
01:15Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
85
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure...
85